Scientists have revealed how cancer can resist PARP inhibitors, a precision medicine used to treat thousands of patients worldwide.

The first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial. The drug, called NXP800, was discovered at The Institute of Cancer Research, London, and targets the pathway regulated by the HSF1 transcription factor.

A combination of five existing drugs keeps cancer at bay for longer in patients with a highly aggressive type of bone marrow cancer, a major new trial reveals.

The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying the development of cutting-edge drugs and technologies.

In December, the NIHR Biomedical Research Centre (BRC) at The Royal Marsden and ICR is running a research-focused advent calendar campaign on Twitter to celebrate research news and successes from the past year.

Six researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, have been named in a list of the world's most influential and innovative researchers over the last decade.

Combining two existing cancer drugs could offer promise for some children with an incurable childhood brain cancer, a new study suggests.

The Royal Marsden NHS Foundation Trust will establish a state-of-the-art liquid biopsy testing facility for cancer clinical diagnostics and research following a partnership with Guardant Health, a leading precision oncology company.

Dr Richard Lee, Consultant Respiratory Physician and Champion for Early Cancer Diagnosis at The Royal Marsden NHS Foundation Trust, has been appointed as the NIHR's national cancer lead for screening, prevention and early detection. Dr Lee will combine his lead NIHR role for screening, prevention and early detection of cancer and non-cancerous conditions with his existing responsibilities.

Researchers at The Royal Marsden, Francis Crick Institute and University College London (UCL) have found immune cell patterns within tumours that can help predict whether patients with kidney cancer will respond to immunotherapy.

Results from the ADAPTeR clinical trial were published in Cancer Cell journal on Thursday 28 October.